Alnylam Pharmaceuticals, Inc. / Inceptive Nucleics, Inc.
2026 · Co-Development · $2.0B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
58
Mixed — partial payoff, real shortfalls.
On June 3, 2026, Alnylam Pharmaceuticals and AI biotech Inceptive (Inceptive Nucleics) — founded by former Transformer co-author Jakob Uszkoreit — formed a three-year strategic AI collaboration to apply Inceptive's generative AI / RNA foundation models to the design and screening of small interfering RNA (siRNA) molecules for Alnylam's RNAi therapeutic platform. Inceptive receives $30 million upfront in cash and equity and is eligible for preclinical, regulatory and commercial milestones bringing the deal's total potential value to up to $2 billion. The collaboration pairs Alnylam's 20+ years of proprietary siRNA data with Inceptive's foundation models to accelerate RNAi discovery productivity in support of Alnylam's 2030 strategy.